Characterization of basal-like breast cancer: An update

Diagnostic Histopathology

Volumn 18, Issue 3, 2012, Pages 104-111

  Ho Yen, Colan ^a   Bowen, Rebecca L ^b   Jones, J L ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ROYAL UNITED HOSPITAL   (United Kingdom)

Author keywords

Basal like; Breast cancer; Histology; Immunohistochemistry; Molecular sub type

Indexed keywords

ALPHA CRYSTALLIN; BETA CRYSTALLIN; BETA4 INTEGRIN; BRCA1 PROTEIN; CYTOKERATIN 17; CYTOKERATIN 5; EPIDERMAL GROWTH FACTOR; LAMININ; MI146B 5P; MICRORNA; MICRORNA 146A; MOLECULAR MARKER; P CADHERIN; RETINOBLASTOMA PROTEIN; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR FOXC1; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BASAL CELL; BASAL CELL CARCINOMA; BASAL LIKE BREAST CANCER; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CANCER GROWTH; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER SCREENING; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; HEREDITARY BREAST CANCER; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MAMMOGRAPHY; MESENCHYME CELL; MOLECULAR PATHOLOGY; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR DIFFERENTIATION;

EID: 84863400157     PISSN: 17562317     EISSN: 18767621     Source Type: Journal    
DOI: 10.1016/j.mpdhp.2011.12.002     Document Type: Article

References (48)

1. Perou C.M., Sørlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000 Aug 17, 406:747-752.
2. Sørlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001 Sep 11, 98:10869-10874.
3. Nagle R.B., Böcker W., Davis J.R., et al. Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells. J Histochem Cytochem 1986 Jul, 34:869-881.
4. Perou C.M. Molecular stratification of triple-negative breast cancers. Oncologist 2011, 16(suppl 1):61-70.
5. Carey L.A., Perou C.M., Livasy C.A., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006 Jun 7, 295:2492-2502.
6. Rakha E.A., Putti T.C., Abd El-Rehim D.M., et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 2006 Mar, 208:495-506.
7. Fulford L.G., Easton D.F., Reis-Filho J.S., et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 2006 Jul, 49:22-34.
8. Livasy C.A., Karaca G., Nanda R., et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006 Feb, 19:264-271.
9. Dabbs D.J., Chivukula M., Carter G., Bhargava R. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod Pathol 2006 Nov, 19:1506-1511.
10. Clark S.E., Warwick J., Carpenter R., Bowen R.L., Duffy S.W., Jones J.L. Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. Br J Cancer 2011 Jan 4, 104:120-127.
11. Sotiriou C., Neo S.Y., McShane L.M., et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003 Sep 2, 100:10393-10398.
12. Liu R., Wang X., Chen G.Y., et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007 Jan 18, 356:217-226.
13. DiMeo T.A., Anderson K., Phadke P., et al. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res 2009 Jul 1, 69:5364-5373.
14. Holstege H., Horlings H.M., Velds A., et al. BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations. BMC Cancer 2010 Nov 30, 10:654.
15. Richardson A.L., Wang Z.C., De Nicolo A., et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 2006 Feb, 9:121-132.
16. Cheang M.C., Voduc D., Bajdik C., et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008 Mar 1, 14:1368-1376.
17. Ihemelandu C.U., Leffall L.D., Dewitty R.L., et al. Molecular breast cancer subtypes in premenopausal African-American women, tumor biologic factors and clinical outcome. Ann Surg Oncol 2007 Oct, 14:2994-3003.
18. Foulkes W.D., Smith I.E., Reis-Filho J.S. Triple-negative breast cancer. N Engl J Med 2010 Nov 11, 363:1938-1948.
19. Nielsen T.O., Hsu F.D., Jensen K., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004 Aug 15, 10:5367-5374.
20. Thike A.A., Cheok P.Y., Jara-Lazaro A.R., Tan B., Tan P., Tan P.H. Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol 2010 Jan, 23:123-133.
21. Rakha E.A., El-Sayed M.E., Green A.R., Paish E.C., Lee A.H., Ellis I.O. Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology 2007 Mar, 50:434-438.
22. Jones C., Ford E., Gillett C., et al. Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes. Clin Cancer Res 2004 Sep 15, 10(18 Pt 1):5988-5997.
23. Manié E., Vincent-Salomon A., Lehmann-Che J., et al. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res 2009 Jan 15, 69:663-671.
24. Allen M.D., Vaziri R., Green M., et al. Clinical and functional significance of α9β1 integrin expression in breast cancer: a novel cell-surface marker of the basal phenotype that promotes tumour cell invasion. J Pathol 2011 Apr, 223:646-658.
25. Bertucci F., Finetti P., Cervera N., et al. How basal are triple-negative breast cancers?. Int J Cancer 2008 Jul 1, 123:236-240.
26. Rakha E.A., Elsheikh S.E., Aleskandarany M.A., et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 2009 Apr 1, 15:2302-2310.
27. Hu Z., Fan C., Oh D.S., et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006 Apr 27, 7:96.
28. Thike A.A., Iqbal J., Cheok P.Y., et al. Triple negative breast cancer: outcome correlation with immunohistochemical detection of basal markers. Am J Surg Pathol 2010 Jul, 34:956-964.
29. Blows F.M., Driver K.E., Schmidt M.K., et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 2010 May 25, 7:e1000279.
30. Mangia A., Malfettone A., Simone G., Darvishian F. Old and new concepts in histopathological characterization of familial breast cancer. Ann Oncol 2011 Jan, 22(suppl 1):i24-i30.
31. Da Silva L., Lakhani S.R. Pathology of hereditary breast cancer. Mod Pathol 2010 May, 23(suppl 2):S46-S51.
32. Lakhani S.R., Jacquemier J., Sloane J.P., et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998 Aug 5, 90:1138-1145.
33. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003 Jul 8, 100:8418-8423.
34. Moyano J.V., Evans J.R., Chen F., et al. AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 2006 Jan, 116:261-270.
35. Burness M.L., Grushko T.A., Olopade O.I. Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker?. Cancer J 2010 Jan-Feb, 16:23-32.
36. López-Knowles E., O'Toole S.A., McNeil C.M., et al. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 2010 Mar 1, 126:1121-1131.
37. Hoeflich K.P., O'Brien C., Boyd Z., et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 2009 Jul 15, 15:4649-4664.
38. Graveel C.R., DeGroot J.D., Su Y., et al. Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci U S A 2009 Aug 4, 106:12909-12914.
39. Mueller K.L., Hunter L.A., Ethier S.P., Boerner J.L. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res 2008 May 1, 68:3314-3322.
40. Hu Z., Fan C., Livasy C., et al. A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med 2009 Mar 16, 7:9.
41. Rydén L., Jirström K., Haglund M., Stål O., Fernö M. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up. Breast Cancer Res Treat 2010 Apr, 120:491-498.
42. Sarrió D., Rodriguez-Pinilla S.M., Hardisson D., Cano A., Moreno-Bueno G., Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 2008 Feb 15, 68:989-997.
43. Storci G., Sansone P., Trere D., et al. The basal-like breast carcinoma phenotype is regulated by SLUG gene expression. J Pathol 2008 Jan, 214:25-37.
44. Gorski J.J., James C.R., Quinn J.E., et al. BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer. Breast Cancer Res Treat 2010 Aug, 122:721-731.
45. Turner N.C., Reis-Filho J.S., Russell A.M., et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007 Mar 29, 26:2126-2132.
46. Rehman F.L., Lord C.J., Ashworth A. Synthetic lethal approaches to breast cancer therapy. Nat Rev Clin Oncol 2010 Dec, 7:718-724.
47. Garcia A.I., Buisson M., Bertrand P., et al. Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. EMBO Mol Med 2011 May, 3:279-290.
48. Blenkiron C., Goldstein L.D., Thorne N.P., et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 2007, 8:R214.